QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=FC86B84DEC34730669ACB575536F6B4F;jsessionid=1620F2CD80B4796FA1734D811E8C9D03;jsessionid=ED73E55F358F0C7A2249FFD2887DABE3;jsessionid=1BD8D24A6FD0C452EFB20E463A584648;jsessionid=10C195F89A6C6B89DFE06053A9992A76 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Identification of novel regulatory NFAT and TFII-I binding elements in the calbindin-D28k promoter i…

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=FC86B84DEC34730669ACB575536F6B4F;jsessionid=1620F2CD80B4796FA1734D811E8C9D03;jsessionid=ED73E55F358F0C7A2249FFD2887DABE3;jsessionid=1BD8D24A6FD0C452EFB20E463A584648;jsessionid=10C195F89A6C6B89DFE06053A9992A76